On July 27, 2026, OHB Pediatrics Ltd. (dba Oak Hill Bio), a clinical-stage rare disease therapeutics company, and Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, announced that they had entered into a definitive business combination agreement. In connection with consummation of the transaction, RACC would redomesticate as a Delaware corporation and be renamed Oak Hill Bio Inc., and its shares of common stock would be listed on the Nasdaq Capital Market under the ticker symbol OAKH. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on IP matters related to the transaction.

Oak Hill Bio is developing rugonersen, an investigational ASO therapy for the treatment of Angelman syndrome, in the pivotal Phase 3 BEACON clinical trial (NCT07605429) which dosed its first patient in July 2026. Angelman syndrome is a devastating neurodevelopmental disorder affecting approximately 30,000 diagnosed patients in the U.S. and European Group of Five countries (EU5) with no approved disease-modifying therapies. 

The Wilson Sonsini team that advised Oak Hill Bio on IP matters related to the transaction includes Laurie McNamara and Yingchun Ni.

For more information, please see Oak Hill Bio’s news release. Additional coverage can be found on Fierce Biotech.